Published in J Clin Psychiatry on June 01, 2012
Biological therapies for eating disorders. Int J Eat Disord (2013) 1.24
Mapping the evidence for the prevention and treatment of eating disorders in young people. J Eat Disord (2014) 0.91
Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans. Br J Pharmacol (2014) 0.80
Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLoS One (2015) 0.79
Meta analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa. J Eat Disord (2014) 0.77
Melanin-concentrating hormone is necessary for olanzapine-inhibited locomotor activity in male mice. Eur Neuropsychopharmacol (2015) 0.75
Neurobiologically informed treatment for adults with anorexia nervosa: a novel approach to a chronic disorder. Dialogues Clin Neurosci (2015) 0.75
Does anxiety improve during weight restoration in anorexia nervosa? A systematic review. J Eat Disord (2015) 0.75
Review: antipsychotics do not increase weight in women with anorexia nervosa. Evid Based Ment Health (2012) 0.75
A randomised trial of Acceptance and Commitment Therapy for Anorexia Nervosa after daycare treatment, including five-year follow-up. BMC Psychiatry (2016) 0.75
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry (2011) 2.75
The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull (2003) 2.67
National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry (2012) 2.52
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry (2013) 2.50
Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry (2013) 2.34
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol (2011) 2.15
Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord (2013) 2.07
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry (2009) 1.82
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry (2013) 1.76
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res (2012) 1.68
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry (2010) 1.65
Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry (2004) 1.63
Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol (2011) 1.63
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res (2012) 1.56
Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology (2010) 1.54
Sudden deaths in psychiatric patients. J Clin Psychiatry (2011) 1.53
Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials. Clin Rehabil (2012) 1.51
Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res (2004) 1.49
The comparison of three renal tumor scoring systems: C-Index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores. J Endourol (2011) 1.48
Moving forward in GME reform: a 4 + 1 model of resident ambulatory training. J Gen Intern Med (2013) 1.46
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry (2007) 1.45
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2013) 1.44
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatry (2013) 1.39
The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull (2003) 1.36
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord (2010) 1.34
Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry (2011) 1.28
Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry (2013) 1.27
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J (2013) 1.25
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry (2009) 1.20
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol (2010) 1.20
Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry (2013) 1.20
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res (2011) 1.15
Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry (2012) 1.14
Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf (2012) 1.13
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry (2013) 1.12
Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry (2005) 1.11
Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int (2012) 1.09
Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry (2008) 1.09
Management of antipsychotic-related weight gain. Expert Rev Neurother (2010) 1.07
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res (2010) 1.06
Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol (2013) 1.05
A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry (2013) 1.03
Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics (2012) 1.02
Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci (2010) 1.02
Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics (2010) 0.99
Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol (2009) 0.98
Treatment models and designs for intervention research during the psychotic prodrome. Schizophr Bull (2003) 0.98
Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry (2012) 0.98
Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res (2012) 0.98
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol (2009) 0.95
Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. Bipolar Disord (2013) 0.95
Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry (2007) 0.95
Development and reliability of the HAM-D/MADRS interview: an integrated depression symptom rating scale. Psychiatry Res (2006) 0.94
Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2012) 0.94
Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry (2008) 0.93
Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant (2013) 0.93
Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. J Affect Disord (2011) 0.92
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull (2013) 0.91
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry (2009) 0.90
Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep (2013) 0.90
Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry (2013) 0.90
The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry (2015) 0.90
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry (2013) 0.89
Patterns of adherence to treatment in adolescents with bipolar disorder. J Child Adolesc Psychopharmacol (2005) 0.89
Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol (2012) 0.89
Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci (2012) 0.89
Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program. Schizophr Bull (2016) 0.88
Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand (2010) 0.88
Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. Bipolar Disord (2014) 0.88
A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol (2011) 0.88
Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.88
The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation. Child Adolesc Psychiatry Ment Health (2008) 0.88
Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord (2012) 0.88
Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res (2011) 0.87
Dysmetabolic Signals in "Metabolically Healthy" Obesity. Obes Res Clin Pract (2012) 0.87
Experts' recommendations for treating maladaptive aggression in youth. J Child Adolesc Psychopharmacol (2011) 0.86
Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. Asian J Psychiatr (2012) 0.86
Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry (2014) 0.86
Do daughters with eating disorders agree with their parents' perception of family functioning? Compr Psychiatry (2005) 0.86
Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J Clin Psychiatry (2010) 0.86
Predictors of insulin resistance in the obese with metabolic syndrome. Eur J Intern Med (2010) 0.85
The impact of an end-of-life communication skills intervention on physicians-in-training. Gerontol Geriatr Educ (2011) 0.85
Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain (2015) 0.85
Frequency and correlates of inappropriate pediatric psychiatric emergency room visits. J Clin Psychiatry (2009) 0.85
Elevated CSF Tau is associated with psychosis in Alzheimer's disease. Am J Psychiatry (2013) 0.84
Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry (2015) 0.84
Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry (2014) 0.84
Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry (2011) 0.84
A review of physical activity correlates in patients with bipolar disorder. J Affect Disord (2012) 0.84